Alerts will be sent to your verified email
Verify Email
BALAXI
|
Balaxi Pharma.
|
Ambalal Sarabhai Ent
|
Gennex Lab
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
27.3 % | 19.11 % | 7.82 % |
|
5yr average Equity Multiplier
|
1.4 | 2.07 | 1.53 |
|
5yr Average Asset Turnover Ratio
|
1.43 | 0.75 | 0.75 |
|
5yr Avg Net Profit Margin
|
11.03 % | 10.89 % | 7.88 % |
|
Price to Book
|
1.14 | 1.87 | 1.54 |
|
P/E
|
13.97 | 20.48 | 20.47 |
|
5yr Avg Cash Conversion Cycle
|
154.28 Days | -37.53 Days | 43.23 Days |
|
Inventory Days
|
87.41 Days | 33.51 Days | 49.12 Days |
|
Days Receivable
|
103.86 Days | 63.69 Days | 50.53 Days |
|
Days Payable
|
63.18 Days | 147.98 Days | 75.36 Days |
|
5yr Average Interest Coverage Ratio
|
57.05 | 9.88 | 6.21 |
|
5yr Avg ROCE
|
36.52 % | 24.01 % | 11.17 % |
|
5yr Avg Operating Profit Margin
|
16.64 % | 5.29 % | 10.47 % |
|
5 yr average Debt to Equity
|
0.09 | 0.32 | 0.18 |
|
5yr CAGR Net Profit
|
-5.76 % | -30.01 % | 43.63 % |
|
5yr Average Return on Assets
|
18.47 % | 8.69 % | 5.16 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
65.99 % | 31.35 % | 19.83 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 21.79 % |
|
Change in Promoter Holding (3 Yrs)
|
-6.87 % | 0.59 % | -2.22 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Balaxi Pharma.
|
Ambalal Sarabhai Ent
|
Gennex Lab
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Drug Delivery Break-Up
|
Drug Delivery Break-Up
|
-
|
-
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|